

Form **990-PF**

Department of the Treasury
Internal Revenue Service

Return of Private Foundation

or Section 4947(a)(1) Trust Treated as a Private Foundation

Note: You may be able to use a copy of this return to satisfy State reporting requirements

OMB No. 1545-0052

1983

For the calendar year 1983, or tax year beginning 1983, and ending 19

Please type, print, or attach label. See Specific Instructions.

Name of organization

THE KROC FOUNDATION

Employer identification number

36 6125259

Address (number and street) CREEKSIDE PLAZA

5290 OVERPASS ROAD - SUITE 225

State registration number (see instructions)

CA 0578112

City or town, State, and ZIP code

SANTA BARBARA CA 93111

If the foundation is in a 60 month termination under section 507(b)(1)(B) check here ☐

If address changed, check here ☒

Foreign organizations, check here ☐

Fair market value of assets at end of year

53847216

Check type of organization

☒ Exempt private foundation

☐ 4947(a)(1) trust

☐ Other taxable private foundation

Check this box if your private foundation status terminated under section 507(b)(1)(A) ☐

Section 4947(a)(1) trusts filing this form in lieu of Form 1041, check here and see general instructions ☐

The books are in care of

RECEIVED SERVICE CENTER

Located at

401 WEST 4TH ST. SAN FRANCISCO, CA 94104-1000

Part I.—Analysis of Revenue and Expenses (See Instructions for Part I)

	(A) Revenue and expenses per books	(B) Computation of net investment income	(C) Computation of adjusted net income	(D) Disbursements for charitable purpose
Revenue				
1 Contributions, gifts, grants, etc. (attach schedule)	11346			
2 Contributions from split-interest trusts				
3 Membership dues and assessments				
4 Interest on savings and temporary cash investments	10907	10907	10907	
5 Dividends and interest from securities	3157568	3157568	3157568	
6 Gross rents				
7 Net gain or (loss) from sale of assets not on line 11	858.14			
8 Capital gain net income		15196826		
9 Net short-term capital gain			292227	
10 Income modifications				
11 Gross profit from any business activities. (Gross receipts \$ minus cost of sales \$)				
12 Other income (attach schedule) SCH 2	345744	3352	3352	
13 Total—add lines 1 through 12	12105705	18368653	3464054	
Expenses				
14 Compensation of officers, etc.	325000	29000	29000	116000
15 Other salaries and wages	296294	39259	39259	237035
16 Pension plans, employee benefits	14230	3286	3286	13144
17 Investment, legal, and other professional services	109761	12321	12321	
18 Interest				
19 Taxes (attach schedule) SCH 2	383479	4049	4049	16196
20 Depreciation and depletion SCH 3	27730		27730	
21 Occupancy	1281		1281	
22 Other expenses (attach schedule) SCH 3	2353788	15332	15332	2331699
23 Contributions, gifts, grants (from Part XIII) SCH 1	5826977			5826977
24 Total—add lines 14 through 23	9340740	193247	222258	8541051
25 (a) Excess of revenue over expenses: Line 13 minus line 24	2764965			
(b) Net investment income (if negative, enter -0-)		18175406		
(c) Adjusted net income (if negative, enter -0-)			324796	

Part II.—Excise Tax On Investment Income (Section 4940(a), 4940(b), or 4948—See Instructions)

1 Domestic organizations enter 2% of line 25(b). Exempt foreign organizations enter 4% of line 25(b)	363508
2 Tax under section 511 (exempt foundations and exempt foreign organizations enter -0-)	
3 Add lines 1 and 2	363508
4 Tax under subtitle A (exempt foundations and exempt foreign organizations enter -0-)	
5 Tax on investment income (line 3 minus line 4 (but not less than -0-))	
6 Credits: (a) Exempt foreign organizations—tax withheld at source	
(b) Tax paid with application for extension of time to file (Form 2758)	36
7 Tax due (line 5 minus line 6)	
8 Overpayment—(line 6 minus line 5)	

FILMED
10-15-84

Part III.—Balance Sheets

Attached schedules should be for end of year amounts only (See instructions for col. (C).)

		Beginning of year	End of year	
		(A) Book Value	(B) Book Value	(C) Fair Market Value
Assets	1 Cash—non-interest bearing	29905	26962	26962
	2 Savings and temporary cash investments	88719	141774	148774
	3 Accounts receivable ▶			
	minus allowance for doubtful accounts ▶			
	4 Pledges receivable ▶			
	minus allowance for doubtful accounts ▶			
	5 Grants receivable			
	6 Receivables due from officers, directors, trustees, and other disqualified persons (see instructions)			
	7 Other notes and loans receivable ▶			
	minus allowance for doubtful accounts ▶			
	8 Inventories for sale or use	68890	24823	24823
	9 Prepaid expenses and deferred charges			
	10 Investments—securities (attach schedule) <i>Scn 4</i>	43885653	46646284	53373501
	11 Investments—land, buildings, and equipment basis ▶			
	minus accumulated depreciation (attach schedule) ▶			
	12 Investments—mortgage loans			
13 Investments—other (attach schedule)				
14 Land, buildings, and equipment basis ▶ <i>Scn 3</i> 210050				
minus accumulated depreciation (attach schedule) ▶ <i>P-0045</i>				
15 Other assets (Describe ▶ <i>Scn 5</i>)	93755	143151	143151	
16 Total assets (add lines 1 through 15)	44289637	47119999	53847216	
Liabilities	17 Accounts payable and accrued expenses	534934	600331	
	18 Grants payable			
	19 Support and revenue designated for future periods (attach schedule)			
	20 Loans from officers, directors, trustees, and other disqualified persons			
	21 Mortgages and other notes payable (attach schedule)			
	22 Other liabilities (Describe ▶)			
	23 Total liabilities (add lines 17 through 22)	534934	600331	
Fund Balances or Net Worth	Organizations that use fund accounting, check here ▶ <input type="checkbox"/>			
	24 (a) Current unrestricted fund			
	(b) Current restricted funds			
	25 Land, buildings, and equipment fund			
	26 Endowment fund			
	27 Other funds (Describe ▶)			
	Organizations not using fund accounting, check here ▶ <input checked="" type="checkbox"/>			
	28 Capital stock or trust principal	75836991	75836991	
	29 Paid-in or capital surplus			
	30 Retained earnings or accumulated income	632082288	649317323	
	31 Total fund balances or net worth (see instructions)	44289637	46519668	
32 Total liabilities and fund balances/net worth (see instructions)	44289637	47119999		

Part IV.—Analysis of Changes in Net Worth or Fund Balances

1 Total net worth or fund balances at beginning of year—Part III, Column (A), line 31	43734703
2 Enter amount from Part I, line 25(a)	2764966
3 Other increases not included in line 2 (itemize) ▶	
4 Add lines 1, 2, and 3	46519668
5 Decreases not included in line 2 (itemize) ▶	
6 Total net worth or fund balances at end of year (line 4 minus line 5)—Part III, Column (B), line 31	46519668

Part V.—Statements Regarding Activities

File Form 4720 if you answer "No" to question 10(b), 11(b), or 14(b) or "Yes" to question 10(c), 12(b), 13(a), or 13(b).	Yes	No
1 (a) During the tax year, did you attempt to influence any national, State, or local legislation or did you participate or intervene in any political campaign?		✓
(b) Did you spend more than \$100 during the year (either directly or indirectly) for political purposes (see instructions for definition)? If you answered "Yes" to 1(a), or (b), attach a detailed description of the activities and copies of any materials published or distributed by the organization in connection with the activities		✓
(c) Did you file Form 1120-POL?		✓

Part V.—Statements Regarding Activities (continued)

	Yes	No
2 Have you engaged in any activities which have not previously been reported to the Internal Revenue Service? If "Yes" attach a detailed description of the activities.		✓
3 Have you made any changes, not previously reported to the IRS, in your governing instrument, articles of incorporation, or bylaws, or other similar instruments? If "Yes" attach a conformed copy of the changes.		✓
4 (a) Did you have unrelated business gross income of \$1,000 or more during the year?		✓
(b) If "Yes" have you filed a tax return on Form 990-T for this year?	✓	
5 Was there a liquidation, termination, dissolution, or substantial contraction during the year? If "Yes" attach a schedule for each asset disposed of showing: the type of asset, the date of disposition, its cost or other basis, its fair market value on date of disposition, and the name and address of each recipient to whom assets were distributed. (See General Instruction I.)		✓
6 Are the section 508(e) requirements satisfied either: • by language written into the governing instrument, or • by State legislation that effectively amends the governing instrument so that no mandatory directions that conflict with the State law remain in the governing instrument?	✓	
7 Did you have at least \$5,000 in assets at any time during the year? If "Yes" complete Part III, Column (C) and Part XIII.	✓	
8 (a) Enter States to which the foundation reports or with which it is registered (see instructions) ▶ <u>California • Indiana</u>		
(b) If you answered 7 "Yes" have you furnished a copy of Form 990-PF to the Attorney General (or his or her designate) of each State as required by General Instruction K.1? If "No" attach explanation.	✓	
9 Are you claiming status as an operating foundation within the meaning of section 4942(j)(3) or 4942(j)(5) for calendar year 1983 or fiscal year beginning in 1983 (see instructions for Part XII)? If "Yes," complete Part XII.		✓
10 Self-dealing (section 4941). (a) During the year did you (either directly or indirectly): (1) Engage in the sale, or exchange, or leasing of property with a disqualified person? (2) Borrow money from, lend money to, or otherwise extend credit to (or accept it from) a disqualified person? (3) Furnish goods, services, or facilities to (or accept them from) a disqualified person? (4) Pay compensation to or pay or reimburse the expenses of a disqualified person? (5) Transfer any of your income or assets to a disqualified person (or make any of either available for the benefit or use of a disqualified person)? (6) Agree to pay money or property to a government official? (Exception: check "No" if you agreed to make a grant to or to employ the official for a period after he or she terminates government service if he or she is terminating within 90 days.) (b) If you answered "Yes" to any of the questions 10(a)(1) through (6), were the acts you engaged in excepted acts as described in regulations section 53.4941(d)-3 and 4? (c) Did you engage in a prior year in any of the acts described in 10(a), other than excepted acts, that were acts of self-dealing that were not corrected by the first day of your tax year beginning in 1983?		✓ ✓ ✓ ✓ ✓ ✓ ~1/4 ✓
11 Taxes on failure to distribute income (section 4942) (does not apply for years you were an operating foundation as defined in section 4942(j)(3) or 4942(j)(5)). (a) Did you at the end of tax year 1983 have any undistributed income (lines 6(d) and (e), Part XI) for tax year(s) beginning before 1983? If "Yes" list the years ▶ (b) If "Yes" to (a) above, are you applying the provisions of section 4942(a)(2) (relating to incorrect valuation of assets) to the undistributed income for ALL such years? (c) If the provisions of section 4942(a)(2) are being applied to ANY of the years listed in (a) above, list the years here and see the instructions ▶		✓ ~1/4
12 Taxes on excess business holdings (section 4943). (a) Did you hold more than 2% direct or indirect interest in any business enterprise at any time during the year? (b) If "Yes" did you have excess business holdings in 1983 as a result of any purchase by you or disqualified persons after May 26, 1969; after the lapse of the 5-year period to dispose of holdings acquired by gift or bequest, or after the lapse of the 10-year first phase holding period? Note: You may use Schedule C, Form 4720, to determine if you had excess business holdings in 1983.		✓ ~1/4
13 Taxes on investments which jeopardize charitable purposes (section 4944). (a) Did you invest during the year any amount in a manner that would jeopardize the carrying out of your charitable purposes? (b) Did you make any investment in a prior year (but after December 31, 1969) that could jeopardize your charitable purpose that you had not removed from jeopardy on the first day of your tax year beginning in 1983?		✓ ✓

Part V.—Statements Regarding Activities (continued)

14 Taxes on taxable expenditures (section 4945)

(a) During the year did you pay or incur any amount to:

- (1) Carry on propaganda, or otherwise attempt to influence legislation by attempting to affect the opinion of the general public or any segment thereof, or by communicating with any member or employee of a legislative body, or by communicating with any other government official or employee who may participate in the formulation of legislation?
- (2) Influence the outcome of any specific public election, or to carry on, directly or indirectly, any voter registration drive?
- (3) Provide a grant to an individual for travel, study, or other similar purposes?
- (4) Provide a grant to an organization, other than a charitable, etc., organization described in section 509(a) (1), (2), or (3)?
- (5) Provide for any purpose other than religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals?

(b) If you answered "Yes" to any of questions 14 (a)(1) through (a)(5), were all such transactions excepted transactions as described in regulations section 53.4945?

(c) If you answered "Yes" to question 14(a)(4), do you claim exemption from the tax because you maintained expenditure responsibility for the grant?

If "Yes" attach the statement required

15 Did any persons become substantial contributors during the tax year?

If "Yes" attach a schedule listing their names and addresses.

16 During this tax year did you maintain any part of your accounting/tax records on a computerized system?

Part VI.—Information About Officers, Directors, Trustees, Foundation Managers, Highly Paid Employees and Contractors

1 List officers, directors, trustees, foundation managers and, if paid, their compensation for 1983 (see instructions).

Name and address	Title, and average hours per week devoted to position	Contributions to employee benefit plans	Expense account, other allowances	Compensation
STATEMENT 7				
Total				320625

2 Compensation of five highest paid employees for 1983 (other than included in 1 above—see instructions)

Name and address of employees paid more than \$30,000	Title and time devoted to position	Contributions to employee benefit plans	Expense account other allowances	Compensation
WALTER F. GABLY, 1124 MINGACH DR. SANTA YVES CA 94060	Director CREDIT PROGRAM FULL TIME	12920	-	46630
C. DONALD WHEATON, SECRETARY 100 Ocean Ave Santa Barbara CA 93102	Director SUPERINTENDENT PROGRAM FULL TIME	5600	-	50400
ROBERT J. FARRAR, 6255 Camino Mission Rd # 227 San Diego CA 92108	Coordinator of CARE FOR PROGRAM FULL TIME	-	-	22352

Total number of other employees paid over \$30,000 ▶

3 Five highest paid persons for professional services for 1983 (see instructions)

[illegible]

Total number of others receiving over \$30,000 for professional services ▶ —

Part VII.—Capital Gains and Losses for Tax on Investment Income *SCHEDULE C*

a. Kind of property. Indicate security, real estate, or other (specify)	b. Description (examples: 100 sh. of "Z" Co., 2 story brick, etc.)	c. How acquired P—Purchase D—Donation	d. Date acquired (mo., day, yr.)	e. Date sold (mo., day, yr.)
1 _____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
f. Gross sales price minus expense of sale	g. Depreciation allowed (or allowable)	h. Cost or other basis	i. Gain or (loss) (f plus g minus h)	
_____	_____	_____	_____	
_____	_____	_____	_____	
_____	_____	_____	_____	
_____	_____	_____	_____	
_____	_____	_____	_____	
_____	_____	_____	_____	
_____	_____	_____	_____	
Complete only for assets showing gain in column i and owned by the foundation on 12/31/69				m. Losses (from col. i) Gains (excess of col. i gain over col. l, but not less than zero)
j. F.M.V. as of 12/31/69	k. Adjusted basis as of 12/31/69	l. Excess of col. j over col. k, if any		
_____	_____	_____		
_____	_____	_____		
_____	_____	_____		
_____	_____	_____		
_____	_____	_____		
_____	_____	_____		
_____	_____	_____		
2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 8 } If (loss), enter -0- in Part I, line 8 }	Scn C		15196826	
3 Net short-term capital gain (loss) as defined in section 1222(5) and (6) If gain, also enter in Part I, line 9 (see instructions for line 9) If loss, enter -0- in Part I, line 9 }	Scn C		292227	

Part VIII.—Minimum Investment Return for 1983

1	Fair market value of assets not used (or held for use) directly in carrying out charitable, etc., purposes:	
(a)	Average monthly fair market value of securities	45 081 967
(b)	Average of monthly cash balances	10 412 621
(c)	Fair market value of all other assets (see instructions)	297 979
(d)	Total (add lines (a), (b), and (c))	55 792 567
2	Acquisition indebtedness applicable to line 1 assets	
3	Line 1(d) minus line 2	55 792 567
4	Cash deemed held for charitable activities—enter 1½% of line 3 (for greater amount, see instructions)	836 888
5	Line 3 minus line 4	54 955 679
6	Enter 5% of line 5	27 477 84

Part IX.—Computation of Distributable Amount for 1983 (See instructions)

1	Minimum investment return from Part VIII, line 6		2747784
2	Total of:		
	(a) Tax on investment income for 1983 from Part II, line 5	3635.8	
	(b) Income tax under subtitle A, for 1983		3635.8
3	Distributable amount (line 1 minus line 2)		2384276
4	Adjustments to distributable amount		
5	Distributable amount as adjusted (line 3 plus or minus line 4)—also enter in Part XI, line 1		2384276

Part X.—Qualifying Distributions in 1983 (See instructions)

1 Amounts paid (including administrative expenses) to accomplish charitable, etc., purposes	
(a) Expenses, contributions, gifts, etc.—total from Part I, column (D), line 24	854,051
(b) Program-related investments	
2 Amounts paid to acquire assets used (or held for use) directly in carrying out charitable, etc., purposes	
3 Amounts set aside for specific charitable projects that satisfy the:	
(a) Suitability test (prior IRS approval required)	
(b) Cash distribution test (attach the required schedule)	
4 Total qualifying distributions made in 1983 (add lines 1, 2, and 3)—also enter in Part XI, line 4	854,051

Part XI.—Computation of Undistributed Income (See instructions)

	(a) Corpus	(b) Years prior to 1982	(c) 1982	(d) 1983
1 Distributable amount for 1983 from Part IX				2384276
2 Undistributed income, if any, as of the end of 1982:				
(a) Enter amount for 1982			-	
(b) Total for prior years:		-		
3 Excess distributions carryover, if any, to 1983:				
(a) From 1978	470,312			
(b) From 1979	4645092			
(c) From 1980	454,892			
(d) From 1981	2989277			
(e) From 1982	51,2795			
(f) Total of 3(a) through (e)	22992177			
4 Qualifying distributions for 1983 (854,051)				
(a) Applied to 1982, but not more than line 2(a)			(-)	
(b) Applied to undistributed income of prior years (Election required)		(-)		
(c) Treated as distributions out of corpus (Election required)	-			
(d) Applied to 1983 distributable amount				(2384276)
(e) Remaining amount distributed out of corpus	6156775			
5 Excess distributions carryover applied to 1983 (If an amount appears in column (d), the same amount must be shown in column (a))	(-)			(-)
6 Enter the net total of each column as indicated below:				
(a) Corpus. Add lines 3(f), 4(c), and 4(e). Subtract line 5	29148952			
(b) Prior years' undistributed income. Line 2(b) minus line 4(b)		(b) -		
(c) Enter the amount of prior years' undistributed income for which a notice of deficiency has been issued, or on which the section 4942(a) tax has been previously assessed		(c) -		
(d) Subtract line 6(c) from line 6(b). This amount is taxable—(see instructions)		(d) -		
(e) Undistributed income for 1982. Line 2(a) minus line 4(a). This amount is taxable—(see instructions)			-	
(f) Undistributed income for 1983. Line 1 minus lines 4(d) and 5. This amount must be distributed in 1984				-
7 Amounts treated as distributions out of corpus to satisfy requirements imposed by section 170(b)(1)(D) or 4942(g)(3) (see instructions)	(-)			
8 Excess distributions carryover from 1978 not applied on line 5 or line 7 (see instructions)	(470,312)			
9 Excess distributions carryover to 1984. (Line 6(a) minus lines 7 and 8)	24445831			
10 Analysis of line 9:				
(a) Excess from 1979	4645092			
(b) Excess from 1980	454,892			
(c) Excess from 1981	2989277			
(d) Excess from 1982	51,2795			
(e) Excess from 1983	6156775			

Part XIII.—Supplementary Information (continued)**3 Information Regarding Grant and Loan Programs**

If you award grants, scholarships, fellowships, loans, prizes, or similar benefits, enter the following information:

(a) The name, address, and telephone number of the person to whom applications should be addressed

Dr. Walter F. Garvey - Director Grants Program (605) 747-2302
529. Overpass Rd. 0 225 Santa Barbara CA 93111

(b) The form in which applications should be submitted and information and materials they should include

APPLICATIONS, IN LETTER FORM, 1 1/2 PAGES IN LENGTH, EXPLAINING THE PURPOSE OF THE GRANTING & DESCRIPTION OF THE RESEARCH INVOLVED

(c) Any submission deadlines

None

(d) Any restrictions or limitations on awards, such as by geographical areas, charitable fields, kinds of institutions, or other factors

See SIMT 8 ATTACHED: THE KROC FOUNDATION "GUIDELINES FOR MEDICAL RESEARCH GRANTS"

4 Grants and Contributions Paid During the Year or Approved for Future Payment

Recipient	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation Status of Recipient	Purpose of grant or contribution	Amount
Name and address (home or business)				
(a) Paid during year				
SCHEDULE 1 ALL GRANTS ARE FOR MEDICAL / SCIENTIFIC RESEARCH. NO RECIPIENT IS RELATED TO THE KROC FOUNDATION IN ANY WAY	NONE	-	SCHEDULE 1	5,826,977
Total (Enter this amount on line 23, Part I, also.)				5,826,977
(b) Approved for future payment				
Total				

Part XIV.—Public Inspection

- 1 Enter the date the notice of availability of the annual return appeared in a newspaper ▶ 7/5/84
- 2 Enter the name of the newspaper ▶ SANTA BARBARA NEWS PRESS
- 3 Check here ☒ if you have attached a copy of the newspaper notice as required by the instructions. (If the notice is not attached, the return will be considered incomplete.)

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief it is true, correct and complete. Declaration of preparer (other than taxpayer or fiduciary) is based on all information of which preparer has any knowledge.

Signature of officer or trustee

7/13/84

Date

Ant. Secretary

Title

Paid Preparer's Use Only

Preparer's signature

Richard H. Russell

Date

7/13/84

Check if self-employed

☒

Firm's name (or yours, if self-employed) and address

CORPORATE ACCOUNTANTS
401 WEST 4 ST. #1000 SAN DIEGO CA

E.I. No.

15-541887

ZIP code

94101

Please Sign Here

**In the Superior Court of the State of California
In and for the County of Santa Barbara**

In the Matter of . . . THE KROC FOUNDATION . . .

NOTICE OF AVAILABILITY OF ANNUAL REPORT

**PROOF OF PUBLICATION
(2015.5 C.C.P.)**

STATE OF CALIFORNIA }
County of Santa Barbara } ss.

I am a citizen of the United States and a resident of the County aforesaid; I am over the age of eighteen years, and not a party to or interested in the above entitled matter. I am the principal clerk of the printer of the Santa Barbara News-Press, a newspaper of general circulation, printed and published daily in the City of Santa Barbara, County of Santa Barbara, and which newspaper has been adjudged a newspaper of general circulation by the Superior Court of the County of Santa Barbara, State of California, under date of June 9, 1952, Case Number 47171; that the notice herein mentioned was set in type not smaller than nonpareil and was preceded by words printed in black-face type not smaller than nonpareil, describing in general terms the purport and character of the notice intended to be given; that the notice, of which the annexed is a printed copy, has been published in each regular issue of said Santa Barbara News-Press on the following dates, to-wit:

July 5

all in the year 19. . . 84.

I hereby certify (or declare) under penalty of perjury that the foregoing is true and correct.

Executed this . . . 9th . . . day of . . . July . . . , 19. . . 84 . . . , at Santa Barbara, CA.



Doni [Signature]
Signature

GRANTS IN EFFECT
1983

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
E. Richard Stanley, Ph.D. Albert Einstein College of Medicine	Control of macrophage proliferation and function	\$ 9,609
Kevin J. Lafferty, Ph.D. Australian National University	Human islet transplantation	17,199
D. G. Patel, Ph.D. Barbara Kopp Geriatric Research Center	Lack of glucagon response to insulin- hypoglycemia in diabetic rats and its mode of action	15,400
Dana Giulian, M.D., Ph.D. Baylor College of Medicine	Isolation of glial stimulatory factors from regenerating neural tissue	10,000
Ravi Iyengar, Ph.D. Baylor College of Medicine	Development and characterization of monoclonal antibodies against the hepatic glucagon receptor	3,000
Charlotte A. Tate, Ph.D. Baylor College of Medicine	Exercise-induced hypoglycemia in insulin- dependent diabetes mellitus	7,269
Terry B. Strom, M.D. Beth Israel Hospital	The relationship between immuno- senescence and responsiveness to insulin and T cell growth factor	28,395
John I. Loewenstein, M.D. Boston University Medical Center	Retinal oxygen measurement in diabetes mellitus	-0-
John B. O'Sullivan, M.D. Boston University Medical Center	Diabetes 25 years after exposure to hyperglycemia in utero	36,707
Jean D. Sipe, Ph.D. Boston University School of Medicine	The role of interleukin 1 in acute and chronic inflammation	34,282
Howard L. Weiner, M.D. Davis M. Dawson, M.D. Brigham and Women's Hospital	Outpatient immunosuppressive treatment of multiple sclerosis	8,750
Roland K. Robins, Ph.D. Brigham Young University	Potential antiviral agents for the treatment of multiple sclerosis and diabetes mellitus	28,841
Patrick W. Mobley, Ph.D. Larry M. Gordon, Ph.D. California State Polytechnic University Pomona	The role of hepatic membrane lipid composition and fluidity in membrane function and the insulin resistance of the Ob/Ob mouse	-0-

1983 Grants (continued)
Schedule 1

The Kroc Foundation
36-6125258

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Arnold I. Caplan, Ph.D. Case Western Reserve University	Mesodermal modulating factor	\$ 40,000
Howard Gershman, Ph.D. Case Western Reserve University	Induction of collagenase in animal synovium	26,472
Richard W. Hanson, Ph.D. Case Western Reserve University	The introduction of an insulin and cAMP regulated gene into whole animals	3,000
Thomas F. Kresina, Ph.D. Case Western Reserve University	A study of the idiotypy of anti-collagen antibody molecules and their pathogenesis in experimental immune synovitis	3,000
Irving Kushner, M.D. Case Western Reserve University	Regulation of biosynthesis of murine amyloid-associated proteins	-0-
Vincent M. Monnier, M.D. Robert R. Kohn, M.D., Ph.D. Case Western Reserve University	Correlation between browning of skin collagen and long-term sequelae of diabetes	8,529
Neil E. Reiner, M.D. Nai-Kong V. Cheung, M.D., Ph.D. Case Western Reserve University	The induction of immunologic unrespon- siveness to insulin	19,920
Yves Borel, M.D. Children's Hospital Medical Center Boston	Preparation of oligonucleotide-protein carrier conjugates	29,250
Allen S. Goldman, M.D. The Children's Hospital of Philadelphia	Studies of the mechanism of the diabetic embryopathy	8,750
Pierre DeMeyts, Ph.D. Yoko Fujita Yamaguchi, Ph.D. Rachmiel Levine, M.D. City of Hope Research Institute	Evaluation of the kinetic properties of the purified insulin receptor	7,425
Frederick T. Greenaway, Ph.D. Clark University	The role of copper in the action of lysyl oxidase	18,908
Elizabeth Simpson, M.D., VetM.B. Clinical Research Centre Middlesex, England	The use of H-Y specific T cell clones to explore Ir gene control of immune reactivity	-0-
David H. Neil, M.R.C.V.S. Colorado State University	Genetic selection for small body size in the Yucatan miniature pig	43,559
Kenneth Sterling, M.D. Columbia University College of Physicians and Surgeons	Effect of thyroid hormone on carbohydrate metabolism	8,635

1983 Grants (continued)
Schedule 1

The Kroc Foundation
36-6125258

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Collin J. Weber, M.D. Columbia University College of Physicians and Surgeons	Tissue culture isolation and xenotransplantation of fetal and neonatal primate and bovine pancreatic islets	\$ 27,672
Kurt H. Stenzel, M.D. Marcus M. Reidenberg, M.D. Cornell University	Immunoregulatory dysfunction induced by drugs that cause lupus-like syndrome	34,936
Brian Summers, Ph.D. Cornell University	A study of canine distemper virus in canine cerebellar explants: viral demyelinating encephalitis <u>in vitro</u>	29,306
Peter Hasselbacher, M.D. Dartmouth Medical School	Mechanisms of joint destruction in chronic gout	34,806
Allan Munck, Ph.D. Paul M. Goyre, Ph.D. Dartmouth Medical School	Mechanisms of anti-inflammatory actions of glucocorticoids and prostaglandins: modulation of Fc receptors	27,938
Dolph O. Adams, M.D., Ph.D. Duke University	Cytolytic proteases from mononuclear phagocytes in rheumatoid arthritis: effects on connective tissue cell and their regulation	14,789
Eugene D. Day, Ph.D. Deepak Bastia, Ph.D. Duke University	The production of highly purified human myelin basic protein fragments in <u>E. coli</u> by means of specific oligonucleotide- directed synthesis	20,000
David Patterson, Ph.D. Eleanor Roosevelt Institute for Cancer Research	Molecular analysis of genetic regulation of purine synthesis	29,870
John K. Spitznagel, M.D. John S. McDougal, M.D. Emory University	Immunological studies of the arthritis induced in rats by heat-killed strep- tococci	10,000
Sergio L. Abreu, Ph.D. Fordham University	Effects of interferon on experimental allergic encephalomyelitis and adjuvant arthritis	47,100
Allen M. Spiegel, M.D. Foundation for Bio-Medical Research and Education In- corporated	Monoclonal antibodies to parathyroid cell surface antigens	4,165
Harry Keen, M.D., F.R.C.P. Guy's Hospital London, England	Metabolic normalization and microvascular disease	10,740

1983 Grants (continued)
Schedule 1

The Kroc Foundation
36-6125258

Principal Investigator and Institution	Title of Project	Amount
Dan Eilat, Ph.D. Hadassah University Hospital Jerusalem, Israel	Molecular structure and antigenic specificity of SLE hybridoma anti- bodies	\$ 7,900
Miles Fox, M.D., Ch.M., F.R.C.S. Hallamshire Hospital Sheffield, England	Transplantation of rat pancreas and kidney utilizing combined technique and immunological monitoring	3,000
Alfred L. Goldberg, M.D. Harvard Medical School	The rapid degradation of insulin and other hormones in bacterial cells	29,439
Jack L. Strominger, M.D. Harvard University	Genetic analysis of the HLA-DR region of the human MHC and its relation to multiple sclerosis, juvenile diabetes and rheumatoid arthritis	42,576
Flora de Pablo, M.D., Ph.D. Hospital de la Santa Creu I Sant Pau Barcelona, Spain	The role of insulin in fetal develop- ment: implications for normal and abnormal embryogenesis	-0-
Aaron Posner, Ph.D. Joseph M. Lane, M.D. The Hospital for Special Surgery	Mineral characterization of osteo- porotic bone	3,000
Ronald N. Margolis, Ph.D. Howard University	Glycogen metabolism in liver during development of the rat	33,066
Douglas L. Coleman, Ph.D. The Jackson Laboratory	Evaluation of therapeutic effects of dehydroepiandrosterone on diabetes	32,096
George H. Sack, Jr., M.D., Ph.D. The John F. Kennedy Institute	The amyloid genes in arthritis and inflammatory diseases	10,000
Elaine L. Alexander, M.D., Ph.D. Johns Hopkins University	Murine models of immune-mediated central nervous system disease in human rheumatic disorders	9,959
Diane E. Griffin, M.D., Ph.D. Johns Hopkins University	The pathogenesis of protein abnormalities in the cerebrospinal fluid during diabetes	31,552
Richard T. Johnson, M.D. Johns Hopkins University	The pathogenesis of measles encephalitis in Lima, Peru	34,198
M. Daniel Lane, Ph.D. Johns Hopkins University	Regulation of the synthesis, processing and turnover of the insulin receptor in the liver cell	22,100
Gihan Tennekoon, M.D. Guy M. McKhann, M.D. Johns Hopkins University	Regulation of myelination by Schwann cells <u>in vitro</u>	30,461

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Thomas T. Aoki, M.D. Joslin Research Laboratory	C-peptide kinetics in normal, type I and II diabetes mellitus	\$ 27,000
George S. Eisenbarth, M.D., Ph.D. Joslin Research Laboratory	Study of antibody B6: a human monoclonal anti-islet antibody	17,750
Hans Wigzell, M.D., Ph.D. Lars Klareskog, M.D., Ph.D. Karolinska Institute	Specificity of arthritogenic immune responses	19,250
Neville Marks, Ph.D. The Kline Research Institute	Brain thiol proteinase inhibitors and demyelinating conditions	7,784
Herbert S. Diamond, M.D. Steven Carsons, M.D. Long Island Jewish-Hillside Medical Center	Structure and function of synovial fluid fibronectin	30,366
Wendy B. Macklin, Ph.D. Prescott L. Deininger, Ph.D. Louisiana State University	Isolation of the myelin proteolipid and basic protein genes	3,000
Joseph P. Michalski, M.D. Candace C. McBombs, Ph.D. Louisiana State University	Lymphocyte abnormality underlying a genetic predisposition to autoimmunity	14,740
Lloyd Axelrod, M.D. Massachusetts General Hospital	Regulation of prostacyclin production by isolated adipocytes	40,497
Robert B. Colvin, M.D. Massachusetts General Hospital	Suppression of experimental allergic encephalomyelitis by anti-idiotypes	16,490
Laurie H. Glimcher, M.D. Massachusetts General Hospital	Examination of cell surface structures on the autoreactive T cell by monoclonal antibodies	7,500
Robert W. Mann, Sc.D. Massachusetts Institute of Technology	Local stress concentration in the patho- genesis of osteoarthritis	8,155
Alexander Rich, M.D. Massachusetts Institute of Technology	The search for antibodies against nuclear Z-DNA binding proteins in animals and in humans with systemic lupus erythematosus or other autoimmune diseases	7,650
Thomas W. Bunch, M.D. Mayo Clinic and Medical School	Controlled trial of lymphapheresis in rheumatoid arthritis	5,150
F. John Service, M.D. Mayo Clinic and Medical School	Metabolic normalization and micro- vascular disease	2,837
Thomas A. Huff, M.D. Medical College of Georgia	The relation of non-enzymatic glycosylation of lens crystallin to cataract formation in diabetes	-0-

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
G. Colin Budd, Ph.D. Ben Pansky, Ph.D., M.D. Medical College of Ohio	Identification of insulin-like immunoreactivity in cells of the anterior pituitary gland	\$ 25,891
George H. DeVries, Ph.D. Medical College of Virginia	The influence of axonal membrane on glial cell proliferation and differentiation	41,779
James M. May, M.D. Medical College of Virginia	Affinity labeling of the adipocyte hexose carrier: studies on the mechanism of hexose transport stimulation by insulin	-0-
James W. Putney, Jr., Ph.D. Medical College of Virginia	Mechanism of action of glucose releasing hormones in the liver	21,652
Herman S. Cheung, Ph.D. Medical College of Wisconsin	The role of chondrocytes in the pathogenesis of crystal deposition diseases	35,169
Susan Koethe, Ph.D. Medical College of Wisconsin	Manipulation of immunoregulation by plasmapheresis and other therapies in persons with multiple sclerosis	27,499
Neil S. Mandel, Ph.D. Gretchen S. Mandel, Ph.D. Medical College of Wisconsin	The mechanism of calcium pyrophosphate crystal deposition in pseudogout	34,188
Peter G. Sohnle, M.D. Medical College of Wisconsin	The effect of experimental diabetes mellitus on cutaneous <u>Candida albicans</u> infections	20,571
Carol M. Brownschidle, Ph.D. Medical Foundation of Buffalo	The spontaneously diabetic BB rat: an animal model for the study of the effects of maternal diabetes mellitus on pregnancy, fetal maturation and neonatal health	10,230
G. David Smith, Ph.D. Medical Foundation of Buffalo	Crystallographic studies of 4 Zn human insulin	-0-
Jackson B. Pickett, M.D. Medical University of South Carolina	Effect of insulin on neuromuscular transmission	-0-
Gabriel Virella, M.D., Ph.D. Medical University of South Carolina	Detection, isolation and characterization of circulating immune complexes in diabetic patients	-0-
Eugene W. Straus, M.D. Montefiore Hospital and Medical Center	Studies of the content and kinetics of CCK converting enzymes in obese rodent brains	28,055
David W. Hein, Ph.D. Morehouse School of Medicine	The development of a simple, <u>in vitro</u> method, for human acetylator genotype determination	4,587

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Elliot J. Rayfield, M.D. Mount Sinai Medical Center	The mechanism of virus-induced alterations in insulin release	\$ 35,556
Ira D. Goldfine, M.D. Mount Zion Hospital and Medical Center San Francisco	Production of antibodies to IgF receptors and non-human insulin receptors	10,000
Maneth Gravell, Ph.D. National Institutes of Health	Antigenic specificity of antibodies and antibody-producing cells found in the CSF of multiple sclerosis patients	14,038
Vincent C. Hascall, Ph.D. National Institutes of Health	Proteoglycan metabolism in articular cartilage explant cultures	30,160
George S. Johnson, Ph.D. National Institutes of Health	Modulation of glucocorticoid action by ADP-ribosylation of chromosomal proteins	7,051
Hynda K. Kleinman, Ph.D. National Institutes of Health	Isolation and characterization of a collagen binding protein from cartilage	16,428
David M. Neville, Jr., M.D. National Institutes of Health	The design of anti-T cell monoclonal antibody-ricin conjugates which can be used <u>in vivo</u> as T cell suppressants for the treatment of autoimmune diseases	21,438
Peter Nissley, M.D. National Institutes of Health	Development of monoclonal antibodies to insulin-like growth factor receptors	38,000
William E. Paul, M.D. National Institutes of Health	Preparation of a monoclonal antibody to B cell growth factor	7,335
Alfred D. Steinberg, M.D. National Institutes of Health	Study of the pathogenesis of rheumatoid arthritis: regulation of EBV induced immune functions by lymphoid tissue	-0-
Henry deF. Webster, M.D. National Institutes of Health	Intracellular distribution of myelin-associated glycoprotein in oligodendroglia during CNS myelin formation and maintenance	8,820
John H. Freed, Ph.D. National Jewish Hospital and Research Center	Role of Ia antigens in activation of helper T cells	6,875
Vincent Agnello, M.D. New England Medical Center Hospital	Studies on low molecular weight DNA-anti-DNA complexes in systemic lupus erythematosus	41,646
Pankaj D. Mehta, Ph.D. New York State Institute for Basic Research in Mental Retardation	Oligoclonal IgG bands in possible MS and optic neuritis	6,765

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Rochelle Hirschhorn, M.D. New York University Medical Center	Adenosine receptors in systemic lupus erythematosus	\$ 39,986
David A. Moscatelli, Ph.D. New York University Medical Center	Purification and characterization of an angiogenic factor from retina	31,443
Victor Nussenzweig, M.D. New York University Medical Center	Complement receptor defects in patients with circulating immune complexes	35,082
G. Jeanette Thorbecke, M.D. New York University Medical Center	Studies on the role of auto-anti-idiotypic antibody in the prevention of arthritis in mice	3,000
Jerry R. Mandell, M.D. Ohio State University	Ultrastructural immunocytochemical local- ization of the P2 protein in peripheral nervous system	-0-
Ronald L. Whisler, M.D. Ohio State University	B cell function in human autoimmunity	36,928
Wesley W. Bullock, Ph.D. Oregon Health Sciences University	Regulation of human neutrophils by monosaccharide-inhibitable lymphocyte signals	58,037
Gerrie A. Leslie, Ph.D. Oregon Health Sciences University	New approaches in understanding biological functions of IgD	9,975
Charles Howard, Jr., Ph.D. Oregon Regional Primate Research Center	Islet cell antibodies in type II human diabetics	-0-
Barry M. Brenner, M.D. Peter Bent Brigham Hospital	Vasoactive hormone - glomerular receptor interactions in experimental diabetes mellitus	39,396
Terry B. Strom, M.D. Peter Bent Brigham Hospital	The relationship between immunosenescence and responsiveness to insulin and T cell growth factor	8,960
Van C. Mow, Ph.D. Rensselaer Polytechnic Institute	Structure and function of proteoglycans of normal and osteoarthritic cartilage	43,712
Richard L. Stevens, Ph.D. Robert B. Brigham Hospital	Somatomedin and insulin control of proteoglycan biosynthesis in the human chondrocyte	26,954
Anthony Cerami, Ph.D. The Rockefeller University	Role of 16 α -hydroxyestrone-protein adducts in the pathogenesis of lupus erythematosus	30,417

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Robert G. Lahita, M.D., Ph.D. The Rockefeller University	Studies of human sex hormone metabolism in the autoimmune diseases	\$ 7,675
Ralph Steinman, M.D. The Rockefeller University	The contribution of dendritic cells to rheumatoid arthritis	3,000
Darrell Doyle, Ph.D. Roswell Park Memorial Institute	Transfer of the plasma membrane receptor for insulin from hepatocytes to cells not responsive to insulin	29,161
Heinz Kohler, M.D., Ph.D. Roswell Park Memorial Institute	Immunomodulation via idiotypic network	9,589
Leonard C. Harrison, M.D. Royal Melbourne Hospital Victoria, Australia	Chemistry and biological significance of insulin-receptor disulfide exchange	30,189
Eva M. Kohner, M.D., F.R.C.P. Royal Postgraduate Medical School London, England	Metabolic normalization and microvascular disease	31,350
Robert W. Simpson, Ph.D. Rutgers University	Viruses associated with rheumatoid arthritis	30,366
T. Joseph McKenna, M.D. St. Vincent's Hospital Dublin, Ireland	The effect of heparin on the renin- angiotensin-aldosterone axis in diabetic patients	6,250
Joy G. Heitzmann, Ph.D. The Salk Institute	An analysis of self-reactive monoclonal antibodies of multiple sclerosis patients	30,000
Argyrios N. Theofilopoulos, M.D. Scripps Clinic and Research Foundation	Idiotypic network in murine systemic lupus erythematosus and rheumatoid arthritis-like disease	30,393
Martin Sonenberg, M.D., Ph.D. Sloan-Kettering Institute for Cancer Research	Growth hormone fragments and insulin interactions	29,478
C. Garrison Fathman, M.D. Stanford University	Specific immunosuppression in therapy of experimental rheumatoid arthritis	44,000
Patricia P. Jones, Ph.D. Stanford University	Identification of glycolipid Ia antigens	13,461
Jeffery D. Kocsis, Ph.D. Stanford University	Studies on demyelination in the central nervous system	3,000
Abdul Matin, Ph.D. Stanford University	Energy metabolism of ureaplasma urealyticum - a possible etiological agent of arthritis	5,500

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Ronald C. Merrell, M.D. Stanford University	The fate of islet cell autografts	\$ 38,513
Bryan D. Myers, M.D. Stanford University	Pathogenesis (and preventability) of diabetic nephropathy	42,000
Gerald M. Reaven, M.D. Stanford University	Abnormal very low density lipoprotein binding in noninsulin dependent diabetes mellitus	35,243
Lawrence Steinman, M.D. Stanford University	The treatment of experimental demyelin- ating disease with monoclonal antibody to the products of immune response genes and to T cell surface antigens	28,875
Samuel Strober, M.D. Stanford University	Treatment of rheumatoid arthritis with total lymphoid irradiation	46,750
Carol M. Brownschidle, Ph.D. State University of New York Buffalo	The spontaneously diabetic BB rat: an animal model for the study of the effects of maternal diabetes mellitus on pregnancy, fetal maturation and neonatal health	5,036
Eugene R. Mindell, M.D. State University of New York Buffalo	The biology osteonecrosis of the osteoarthritic femoral head	3,000
Patricia K. Boyle, M.D. State University of New York Stony Brook	2 DE of spinal fluid and lymphocytes in MS patients	8,093
Lorne M. Golub, D.M.D., M.Sc. Thomas F. McNamara, Ph.D. State University of New York Stony Brook	The effect of diabetes on gingival collagenase and periodontal disease in germfree and conventional rats	33,281
Arthur D. Rosen, M.D. Max I. Hamburger, M.D. State University of New York Stony Brook	Mechanism of immune tissue damage in multiple sclerosis	18,450
Michael V. Viola, M.D. State University of New York Stony Brook	Purification of a bone resorption stim- ulation factor from a Pagetic cell line	7,195
Phillip H. Smith, Ph.D. State University of New York Syracuse	Localization of insulin binding cites in pancreatic islets	35,726
Eddy Karnieli, M.D. Technion Research and Development Foundation	Regulation of glucose transport by insulin in the human adipose cell	17,895

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Stefan Niewiarowski, M.D., Ph.D. Temple University	Fibrinogen receptors on diabetic platelets	\$ 38,500
Robert M. Friedman, M.D. Uniformed Services University of the Health Sciences	The role of interferons in systemic lupus erythematosus	41,000
George B. Brown, Ph.D. University of Alabama in Birmingham	Investigations of the relationships between voltage-sensitive channels and cytoskeletal elements in neurons	10,278
Donald R. DiBona, Ph.D. University of Alabama in Birmingham	Structural correlates of diabetic nephropathy	-0-
Martine Anne Jaworski, M.D. University of Alberta Canada	Passive transfer of diabetes mellitus in the BB rat	15,000
David G. Johnson, M.D. University of Arizona	Metabolic studies with a glucagon antagonist	35,560
Murray Korc, M.D. University of Arizona	Effect of diabetes on epidermal growth factor binding and action in rat pancreas	3,000
Nobuyoshi Shimizu, Ph.D. University of Arizona	Use of human serum proteins to deliver insulin into receptor deficient cells of diabetes	38,500
John R. J. Sorenson, Ph.D. University of Arkansas for Medical Sciences	Anti-inflammatory activity of copper complexes	27,005
George W. Jordan, M.D. University of California Davis	Host defenses in virus induced diabetes mellitus	34,495
Thomas C. Cesario, M.D. University of California Irvine	Detection of interferon in serum and synovial fluid of patients with rheumatic disease	18,776
Gale A. Granger, Ph.D. University of California Irvine	Demonstration of lymphocyte effector molecules in the tissue destructive lesions of rheumatoid arthritis	28,923
George A. Gutman, Ph.D. University of California Irvine	Studies on the serological structure of rat kappa chains using monoclonal antibodies	37,917
Josiah Brown, M.D. University of California Los Angeles	Ontogeny and typing of histocompatibility antigens in human fetuses	14,547

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Michael C. Graves, M.D. University of California Los Angeles	Cytomegalovirus infection of the Schwann cell	\$ 17,050
Jerome M. Hershman, M.D. University of California Los Angeles	Effect of diabetes mellitus on thyro- tropin secretion on rats	20,000
Mary Ann K. Markwell, Ph.D. University of California Los Angeles	Relationship of gangliosides to the onset of multiple sclerosis	20,000
Paul Shapshak, Ph.D. University of California Los Angeles	Identification and localization of measles virus genes in multiple sclerosis and control brains utilizing cloned com- plementary DNA probes	43,286
Wallace W. Tourtellotte, M.D., Ph.D. University of California Los Angeles	MS CNS IgG synthesis and brain glycolipids	42,697
Anthony W. Norman, Ph.D. University of California Riverside	Vitamin D, the pancreas and insulin relationships	30,000
Theodore Friedmann, M.D. University of California San Diego	The molecular basis of X chromosome inactivation	10,000
Elvin Harper, Ph.D. University of California San Diego	Biosynthesis of a collagenase inhibitor in chondrocytes	3,000
Peter W. Lampert, M.D. Richard A. C. Hughes, M.D. University of California San Diego	Immunological reactions in peripheral nerves	2,200
Peter Lampert, M.D. Clayton A. Wiley, M.D., Ph.D. University of California San Diego	Membrane specializations in human demyelinating diseases	17,484
Michael G. Rosenfeld, M.D. University of California San Diego	Newly discovered neuroendocrine hormones in pancreas: function and role in diabetes mellitus	26,250
J. Edwin Seegmiller, M.D. Randall C. Willis, Ph.D. University of California San Diego	New approaches to elucidation and treat- ment of genetic disorders	44,750

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Nathan J. Zvaifler, M.D. University of California San Diego	Immunologic defects in rheumatoid arthritis - the generation of natural killer-like cytotoxic effector cells in the autologous mixed leukocyte reaction	\$ 20,000
Benjamin W. Zweifach, Ph.D. University of California San Diego	Contributory factors to deterioration of microcirculation in diabetes	37,983
Gerald R. Cunha, Ph.D. University of California San Francisco	Diabetes: a developmental approach	35,000
Robert J. Fletterick, Ph.D. University of California San Francisco	Insulin's regulation of phosphorylase	38,188
William F. Ganong, M.D. University of California San Francisco	Relation of the renin-angiotensin system to the secretion of growth hormone and ACTH, and to glucose homeostasis	31,000
Laurence A. Gavin, M.D. University of California San Francisco	Somatostatin - a modulator of T ₃ metabolism	18,146
Jon David Levine, M.D., Ph.D. University of California San Francisco	Role of synovial nociceptors in experimental arthritis	9,595
Jay A. Levy, M.D. University of California San Francisco	Influence of dietary fat on the development of autoimmune disease	39,781
Robert R. McKendall, M.D. University of California San Francisco	Cytotoxicity in multiple sclerosis	19,352
Donald G. Payan, M.D. University of California San Francisco	The modulation of human T-lymphocyte function by C3a(70-77) in rheumatoid arthritis	23,104
Werner Rosenau, M.D. University of California San Francisco	Rheumatic diseases: studies of cellular immune reactions	39,985
William J. Rutter, Ph.D. University of California San Francisco	Isolation and characterization of the structure of the insulin receptor gene and the role of the receptor in the insulin response	30,000
William E. Seaman, M.D. University of California San Francisco	Autoimmunity in androgen resistant BYSB mice	20,643

Schedule 1

36-6125258

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Clayton A. Wiley, M.D., Ph.D. University of California San Francisco	Membrane specializations in human demyelinating diseases	\$ 17,486
Jack P. Antel, M.D. University of Chicago	Mechanism of defective immunoregulation in multiple sclerosis	39,404
Raymond P. Roos, M.D. University of Chicago	DA virus demyelination and persistence	30,792
Arthur H. Rubenstein, M.D. University of Chicago	Metabolic normalization and micro- vascular disease	7,425
Richard C. Elder, Ph.D. University of Cincinnati	Uptake, metabolism and toxicity of gold-based anti-arthritis drugs	10,000
Jerome H. Herman, M.D. University of Cincinnati	Evaluation of mechanisms modulating the activation and release of chondrocyte proteinase activity	6,287
Henry N. Claman, M.D. University of Colorado Health Sciences Center	Drug-induced autoantibodies in mice	7,500
John S. Goff, M.D. University of Colorado Health Sciences Center	Investigation of diabetic diarrhea	-0-
William W. Hay, Jr., M.D. University of Colorado Health Sciences Center	Development of an insulin-free fetal lamb model	6,250
Sylvia J. Kerr, Ph.D. University of Colorado Health Sciences Center	Methylation of membrane components and insulin action	19,040
Stewart Metz, M.D. University of Colorado Health Sciences Center	Metabolism of arachidonic acid in pancreatic islet cells	30,923
Stephen J. Prowse, Ph.D. University of Colorado Health Sciences Center	Xenotransplantation of pancreatic islet tissue	16,268
David W. Talmage, M.D. University of Colorado Health Sciences Center	The mechanism of the acquired tolerance which develops spontaneously to cultured allografts	36,613
Felix Bronner, Ph.D. Gordon Carmichael, Ph.D. University of Connecticut Health Center	Vitamin D and the processing of the calcium-binding protein	7,500

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Steven E. Pfeiffer, Ph.D. Paula Dore-Duffy, Ph.D. University of Connecticut Health Center	Effects of sera, cerebrospinal fluid, and lymphocytes from multiple sclerosis patients on the myelinogenic potential of primary cultures and isolated oligo- dendrocytes of fetal rat brain	\$ 17,939
Lawrence G. Raisz, M.D. University of Connecticut Health Center	Effects of glucocorticoids on bone formation	35,712
Michael V. Viola, M.D. University of Connecticut Health Center	Purification of a bone resorption stimu- lation factor from a Pagetic cell line	13,166
Noel K. Maclaren, M.D. University of Florida	HLA-DR and organ specific autoimmune diseases including insulin dependent diabetes	37,787
Robert I. Misbin, M.D. University of Florida	Effects of insulin-like growth factors on insulin degradation	14,866
Mohan K. Raizada, Ph.D. University of Florida	Regulation of insulin receptors in diabetes mellitus	-0-
Shozo Izui, M.D. University of Geneva Switzerland	Genetic and immunopathogenic mechanisms of rheumatic diseases	6,875
John S. Cowdery, M.D. University of Iowa	Enteric antigen administration in a murine model of systemic lupus erythematosus	10,000
Harold P. Schedl, M.D., Ph.D. University of Iowa	Total parenteral nutrition in the diabetic rat: effects on small intestinal mucosal growth and function	28,201
John M. Weiler, M.D. University of Iowa	Complement regulation of <u>in vitro</u> immunoglobulin biosynthesis	30,560
Theodore A. Kotchen, M.D. University of Kentucky	Mechanism of low renin in diabetes	30,759
Robert L. Hirsch, Ph.D. Kenneth P. Johnson, M.D. University of Maryland	Effects of cloned alpha interferon on immunoregulation in multiple sclerosis	35,919
Mon Lee Shin, M.D. University of Maryland	Effector mechanisms in lymphocyte induced demyelination	15,928
Arthur A. Like, M.D. University of Massachusetts	Studies of the spontaneous juvenile diabetic syndrome of the bio breeding laboratory rat	23,539

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Margo P. Cohen, M.D. University of Medicine and Dentistry of New Jersey	Cultured retinal microvessel cells: a model for study of diabetic retinopathy	\$ -0-
Stuart Cook, M.D. Peter C. Dowling, M.D. University of Medicine and Dentistry of New Jersey	Canine distemper vaccination and multiple sclerosis - a feasibility study	-0-
Timothy J. Regan, M.D. University of Medicine and Dentistry of New Jersey	Left ventricular function and composition in diabetes after continuous insulin infusion	34,670
John A. Hamilton, Ph.D. University of Melbourne Victoria, Australia	An in vitro model of rheumatoid arthritis	17,638
David S. Howell, M.D. University of Miami	Role of matrix vesicles in chondrocalcinosis	-0-
Alphonse R. Burdi, Ph.D. Stanley M. Garn, Ph.D. University of Michigan	Prenatal determinants of human fatness and obesity	31,648
C. William Castor, M.D. Byron E. Anderson, Ph.D. University of Michigan	Connective tissue activation: studies with novel platelet derivatives	25,587
Jack L. Kostyo, Ph.D. University of Michigan	The site of the diabetogenic action of growth hormone	35,098
Miriam H. Meisler, Ph.D. University of Michigan	Differential expression of amylase genes in diabetic mice	3,000
Thomas J. Schnitzer, M.D., Ph.D. University of Michigan	Pathogenesis of avian reovirus arthritis	11,152
Aaron I. Vinik, M.D. University of Michigan	Biologic activity of somatostatin in blood	36,050
Jose Barbosa, M.D. University of Minnesota	Studies of new genetic markers in insulin dependent diabetes mellitus	46,763
David M. Brown, M.D. University of Minnesota	Studies of effects of high protein and altered fatty acid diets on physiologic and pathologic manifestations of diabetic glomerulopathy	10,142
John R. Sheppard, Ph.D. University of Minnesota	Biological regulation of myelin membrane synthesis	19,250

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Joel D. Taurog, M.D. University of Minnesota	Production of cytolytic human T cell clones specific for HLA-B27	\$ 42,788
Sean O'Regan, M.D. University of Montreal	DNA anti-DNA nephritis in situ	-0-
Louis Lippiello, Ph.D. University of Nebraska	Electrical enhancement of articular cartilage regeneration: comparative effect of pulsing electromagnetic fields and pulsing direct current	7,894
Ernest L. Mazzaferri, M.D. University of Nevada	Gastric inhibitory polypeptide receptors in adipocytes and pancreatic beta cells	40,204
James M. Norton, Ph.D. University of New England	Insulin action during erythrocyte development	-0-
R. Philip Eaton, M.D. University of New Mexico	Bioengineering and biomedical development of a programmable/implantable insulin delivery system	26,156
Dennis E. Van Epps, Ph.D. University of New Mexico	Lymphocyte and neutrophil chemotaxis in the synovial tissues of patients with rheumatoid arthritis	35,942
Ralph C. Williams, Jr., M.D. University of New Mexico	Studies of immune dysregulation in connective tissue diseases	19,994
Allen E. Blaurock, Ph.D. University of North Carolina at Chapel Hill	The roles of two myelin proteins in stabilizing the structure of the nerve myelin sheath	1,350
Robert A. Eisenberg, M.D. University of North Carolina at Chapel Hill	Immune complexes in human disease: detection, characterization and isolation	38,500
Jeffrey A. Frelinger, Ph.D. University of North Carolina at Chapel Hill	Role of immune response associated Ia antigens in the brain	38,500
Thomas W. Sadler, Ph.D. University of North Carolina at Chapel Hill	Effects of maternal diabetes on embryonic metabolism	21,702
John H. Schwab, Ph.D. University of North Carolina at Chapel Hill	Pathogenesis of arthritis induced by peptidoglycan-polysaccharide complexes of microbial origin	20,000
Steven J. H. Ashcroft, Ph.D. University of Oxford England	Protein phosphorylation and signal-response coupling in the pancreatic β -cell	-0-

1983 Grants (continued)
Schedule 1

The Kroc Foundation
36-6125258

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Donald H. Gilden, M.D. University of Pennsylvania	Coronavirus A59 induced demyelination	\$ 20,000
Abdolmohammad Rostami, M.D., Ph.D. University of Pennsylvania	Studies on Schwann cells, myelin and mechanisms of myelination and demyelination	3,000
Donald H. Silberberg, M.D. University of Pennsylvania	Role of alpha-fetoprotein in modifying <u>in vitro</u> CNS demyelination	27,063
John D. Fernstrom, Ph.D. University of Pennsylvania	Effects of diabetes on neutral amino acids and brain neurotransmitters	-0-
Theresa L. Whiteside, Ph.D. Robert B. Buckingham, M.D. University of Pittsburgh	Cloning the scleroderma fibroblast	17,016
Robert Adar, Ph.D. Nicholas Cohen, Ph.D. University of Rochester	Behavioral processes in the immuno-pharmacotherapy of autoimmune disease	35,690
Robert M. Herndon, M.D. University of Rochester	Immunologic and immunoelectron microscopic studies of cerebrospinal fluid in multiple sclerosis	40,632
Kenneth McCormick, M.D. University of Rochester	Maternal diabetes and perinatal hepatic metabolism	23,430
Margaret W. Neuman, Ph.D. University of Rochester	Transcellular transport of calcium in osteoblasts and its role in bone mineralization and calcium homeostasis	21,780
Harold P. Jones, Ph.D. University of South Alabama	The role of calmodulin in neutrophil function	27,739
John O. Fleming, M.D. University of Southern California	Coronaviral antigens in multiple sclerosis	34,071
Harvey R. Kaslow, Ph.D. University of Southern California	Regulation of cyclic-nucleotide phosphodiesterase expression	8,723
Ramesh C. Gupta, M.D. University of Tennessee	Identity of antigen(s) in immune complexes	38,933
Karl Folkers, Ph.D. University of Texas Austin	Cooperative research on the synthesis of peptides related to the human growth hormone and having diabetogenic activity	-0-
Karl Folkers, Ph.D. University of Texas Austin	Synthesis of interferon and fragments	-0-
John R. Falck, Ph.D. University of Texas Dallas	Novel pancreatic eicosanoids	9,985

1983 Grants (continued)
Schedule 1

The Kroc Foundation
36-6125258

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Richard B. Silver, M.D. University of Texas Dallas	Pulmonary function in childhood rheumatic diseases	\$ 22,847
J. Donald Smiley, M.D. Sterling E. Moore, M.D. University of Texas Dallas	Calcinosis in scleroderma and similar conditions	28,434
Peter Stastny, M.D. University of Texas Dallas	HLA and the immune response in man; predisposition for rheumatoid arthritis and other diseases	34,293
Grady F. Saunders, Ph.D. University of Texas Houston	Biosynthesis of glucagon	40,189
Ellen L. Simpson, Ph.D. John W. Jacobs, Ph.D. Gregory R. Mundy, M.D. University of Texas San Antonio	Osteoclast activating factor synthesis in rheumatoid arthritis	39,107
John I. Stevens, Ph.D. University of Toronto Canada	Three dimensional cytoarchitecture and quantitative analysis of diabetic periph- eral axons	8,332
Barry C. Oble, Ph.D. University of Utah	Interaction of a mycoplasma mitogen with Ia antigens: role in disease pathogenesis and immunological dysfunction	36,334
Allen B. Edmundson, Ph.D. University of Utah	The application of X-ray crystallography to human rheumatoid arthritis	3,000
Marie M. Griffiths, Ph.D. University of Utah	Immunogenetic studies of collagen-induced arthritis (ECIA) in the rat	14,486
Don H. Nelson, M.D. University of Utah	Relation of insulin effects on phospholipid metabolism to the increased incidence of cardiovascular disease in diabetes mellitus	22,920
Seth H. Pincus, M.D. University of Utah	Genetic mechanisms of idiotypic suppression	4,000
Johannes Veldhuis, M.D. University of Virginia	Actions of insulin on ovarian cells	7,478
Daniel Porte, Jr., M.D. University of Washington	The role of pancreatic islet cell electrical activity in glucose-induced insulin release	15,302
John Dupre, M.D. University of Western Ontario Canada	Metabolic normalization and microvascular disease	11,880

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Matthew D. Davis, M.D. University of Wisconsin	Metabolic normalization and microvascular disease	\$ 3,850
Ian D. Duncan, B.V.M.S., Ph.D. University of Wisconsin	An immunocytochemical study of myelin formation in a canine myelin mutant	8,585
Claes Hellerstrom, M.D., Ph.D. Uppsala University Sweden	Transplantation of fetal pancreas to diabetic patients	39,221
Nada Awn Abumrad, Ph.D. Charles R. Park, M.D. Jane H. Park, Ph.D. Vanderbilt University	Transport of long chain FA: effects of insulin and diabetes	3,000
Kenneth L. Brigham, M.D. Vanderbilt University	Mechanisms of inflammatory injury: interactions between granulocytes and vascular endothelium	3,000
Eve P. Reaven, Ph.D. Veterans Administration Medical Center Palo Alto, California	Effect of age and related environmental variables on insulin secretion and action in the rat	35,469
Paul F. Lacy, M.D. Washington University	Transplantation of islets of Langerhans in primates	87,500
Jay M. McDonald, M.D. Washington University	Insulin regulation of glucose transport in adipocytes	3,000
Philip Osdoby, Ph.D. Washington University	Osteoclast development and function in systemic and inflammatory bone disease	34,592
Gale W. Rafter, Ph.D. West Virginia University	Interleukin 1 and anti-rheumatic drugs	-0-
Luciano G. Frigeri, Ph.D. Whittier Institute for Diabetes and Endocrinology	A new animal model for studying the metabolic actions of pituitary peptides	28,500
F. Arthur McMorris, Ph.D. The Wistar Institute	Regulation of myelination at the molecular level	29,997
David J. Giron, Ph.D. Wright State University	Enhancement of EMC virus by insulin: mechanisms of action	39,430
Francis L. Black, Ph.D. Yale University	Anti-matrix protein antibody in measles virus related diseases	-0-
John Booss, M.D. Yale University	Immunosuppression of B cell function in multiple sclerosis	-0-

**1983 Grants (continued)
Schedule 1**

**The Kroc Foundation
36-612525d**

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
John A. Hardin, M.D. Yale University	Analysis of antideoxyribo- nucleoprotein antibodies from patients with SLE	\$ 3,000
Robert S. Sherwin, M.D. Yale University	Metabolic normalization and microvascular disease	13,600
		<hr/> \$5,700,000
Dartmouth Medical School, Hanover, New Hampshire		72,724
Family Drug Prevention Program		200
Home of the Guiding Hands		300
Childrens Hospital		440
DCS/Pops for Deaf Community Services		100
Comprehensive Health Center		40
Oak Pines School		119
Walk Around America		100
St. Annes Episcopal Church		100
San Diego Police Association		105
California Womens Commission on Alcoholism		200
Memorial Hospital of Santa Barbara		4,874
Research to Prevent Blindness		100
March of Dimes		100
National Multiple Sclerosis Society		1,300
Santa Barbara Zoological Gardens		10,000
Endocrine Society		5,000
IDF Cambridge Seminar Fund		5,000
Arthritis Foundation		50
The Foundation Center		3,500
International Association of Endocrinology Surgeons		5,000
Foudation for BMRE Inc.		5,000
University of Alaska Foundation		500
International Conference on Calcium Regulating Hormones		7,500
Indiana University Foundation		500
American Thyroid Association		3,500
Sansum Medical Research Foundation		<hr/> 625
		<hr/> \$5,826,977

NAME THE KROC FOUNDATIONIDENTIFICATION NO. 36-6125258STATEMENT NO. 2 (1 of 2)YEAR ENDED 1983

PART V 415 - SUBSTANTIVE CONTRIBUTIONS

RAY A KROC

1939 Villa La Jolla CA

Suite 20

La Jolla CA 92037

PART I, Line 1 - CONTRIBUTIONS

RAY A KROC cash

1939 Villa La Jolla CA Suite 20

La Jolla CA 92037

TOTAL

Col A

Col B + C

Col D

11,346

-

-

11,346

-

-

PART I, Line 12 - OTHER INCOME

REVENUE FROM FINIS & BOOKS

GRANT REVENUE

MISCELLANEOUS

ROYALTIES

TOTAL

246,830

-

-

53,807

-

-

1,735

-

-

3,352

3,352

-

245,744

3,352

-

PART I, Line 19 - TAXES

PROPERTY TAXES

FEDERAL ESTATE TAX

TOTAL

20,245

4,049

16,196

363,234

-

-

313,479

4,049

16,196

NAME The Kroc FoundationIDENTIFICATION NO. 36-6125251STATEMENT NO. 2 (2 of 2)YEAR ENDED 1973

PART 1, LINE 22 - OTHER EXPENSES	Col. A			Col. B, C			Col. D		
AUTO EXPENSE	4300						4300		
DUES & SUBSCRIPTIONS	6318						6318		
CONFERENCE EXPENSE	251487						251487		
OFFICE EXPENSE	26317			5243			20974		
PUBLICATION EXPENSE	145178						145178		
TELEPHONE & UTILITIES	17312			1781			15531		
TRAVEL & ENTERTAINMENT	41792			1358			33434		
LIBRARY EXPENSE	1291						1291		
MAINTENANCE & REPAIR	14060						14060		
INSURANCE	60998						60998		
OUTSIDE SERVICES	4943						4943		
MISCELLANEOUS	5454						5454		
OPERATION CODE EXPENSE	1766981						1766981		
LOSS ON DISPOSITION OF EQUIPMENT	6757			-			-		
TOTAL	2353788			15352			2331699		

STATEMENT NO. 4 (1 of 3)YEAR ENDED 1988

Part III, Line 10 - Investments Securities

December 31, 1988

Amortism

Cost

Amort

Government and Corporate Obligations

U.S. Treasury Bond	11.750	02/15/10	\$500,000	\$	448,125	\$	495,625
U.S. Treasury Note	9.750	11/15/85	500,000		498,281		491,875
U.S. Treasury Note	14.000	03/31/86	500,000		498,438		529,220
U.S. Treasury Note	14.125	03/31/84	500,000		497,813		505,000
U.S. Treasury Note	14.500	07/15/89	500,000		497,325		556,560
Federal National Mortgage Association	11.150	05/11/87	500,000		478,281		495,935
Federal National Mortgage Association	15.000	09/10/85	500,000		500,000		530,625
Ontario, Province Note	14.625	08/31/92	500,000		500,000		562,355
Arizona Public Service First Mortgage	12.750	07/01/13	500,000		488,125		464,355
Avon Corporation Note	11.750	10/15/90	500,000		502,500		493,175
Baltimore Gas and Electric	14.750	07/15/92	500,000		498,750		544,625
CBS Note	14.500	06/15/92	500,000		496,875		546,670
Commonwealth Edison	14.250	08/15/92	500,000		495,625		526,565
Dayton Hudson Debenture	10.750	05/01/13	500,000		473,125		433,700
Dresser Industry	11.750	11/01/07	500,000		498,000		461,115
Dupont Debenture	14.150	07/15/84	500,000		500,000		509,240
Florida Power Mortgage	13.125	10/01/12	500,000		497,200		499,075
General Electric Credit Note	13.625	09/15/91	500,000		507,500		527,325
GMAC Debenture	12.000	06/01/05	500,000		495,000		470,940
Honeywell	11.125	11/01/92	500,000		505,000		475,265
Houston Lighting and Power	15.125	03/01/92	500,000		498,125		542,575
Pacific Gas and Electric	13.375	08/01/15	500,000		502,500		499,085
Southeast Banking Note	11.250	04/15/93	500,000		495,625		463,640
Standard Oil Ohio Note	13.375	09/15/92	500,000		496,875		521,215
Texas Eastern Transportation Note	17.000	09/01/91	500,000		506,935		572,490
Xerox Corporation Note	10.625	03/01/93	500,000		495,000		461,095
Boeing Debenture	8.875	06/15/06	400,000		429,000		492,000
Corning Debenture	8.250	12/01/07	400,000		453,250		419,000
Northwest Airlines Debenture	7.500	12/15/07	400,000		427,000		422,000
Union Carbide CV Debenture	10.000	03/15/06	400,000		398,000		460,000

\$14,578,273 \$14,972,345

STATEMENT OF DEPRECIATION

YEAR ENDED 12/31/83

ACCOUNTANT STATIONERS & PRINTERS - LOS ANGELES

STATEMENT NO. 4 (3.1.3)YEAR ENDED 1983

PART III LINE 10 - INVESTMENTS, SECURITIES

	AMT/34	DECEMBER 31, 1983 COST	FMV
Mutual Funds:			
Stein, Roe & Farnham Capital Fund	20,000	\$ 342,050	\$ 528,600
Stein Roe Special Fund	25,000	165,825	443,250
Stein Roe Universe Fund	74,124	<u>1,059,828</u>	<u>1,366,847</u>
		<u>1,567,703</u>	<u>2,338,697</u>
Cash Reserve Funds:			
Stein, Roe & Farnham Cash Reserves, Inc.		<u>18,086,728</u>	<u>18,086,728</u>
Total managed investments		<u>45,819,201</u>	<u>51,611,001</u>
Other investment:			
McDonald's Corporation common stock	25,000	<u>827,083</u>	<u>1,762,500</u>
Total investments		<u>\$46,646,284</u>	<u>\$53,373,501</u>

NAME THE KROG FOUNDATIONIDENTIFICATION NO. 36 6125258STATEMENT NO. 5YEAR ENDED 12/31/83

PART III, LINE 15- OTHER ASSETS

12/31/82

12/31/83

INVENTORIES RECEIVABLE

87,202

128,875

INVENTORIES RECEIVABLE

9.3

12,499

ROYALTIES RECEIVABLE

5650

OTHER RECEIVABLES

1,200

PREPAID EXPENSE

737

98,753

143,151

PART III, LINE 17- ACCRUALS PAYABLE &

ACCRUALS EXPENSES

ACCOUNTS PAYABLE

47,579

29,139

FEDERAL INCOME TAX PAYABLE

48,561

363,800

ACCUMULATED DEPRECIATION - DEPRECIATION

2700

1,468

ACCUMULATED EMPLOYEE RETIREMENT EXPENSE

3,944

3,944

ACCUMULATED TERMINATION BENEFITS

103,330

504,984

600,351

STATEMENT NO. 6 (1032)**SCHEDULE OF CAPITAL GAINS & LOSSES**YEAR ENDED 1985

a. Kind of property and description (Example 100 shares of "Z" Co)	b. Date acquired (mo., day, yr.)	c. Date sold (mo., day, yr.)	d. Gross sales price	e. Cost or other basis as adjusted and expense of sale	f. Gain (or loss) to be taken into account		
					Short-Term	Long-Term Federal, held	
					Not over 12 months	1 to 5 years	Over 5 years
6100 NQDISE BRANDS	1/1/85	1/1/85	22740.1	18367.1			43730
3400 NQDISE BRANDS	1/1/85	1/1/85	143749	117429			26320
3000 NQDISE BRANDS	1/1/85	1/1/85	73718	69680	4038		
1500 FLORIDA POWER LT	9/1/80	4/1/85	55678	51773	3905		
3000 DIBOLD	12/1/81	4/1/85	272251	144915			127336
10000 GENERAL FOODS	9/1/80	2/1/85	877337	875050	2287		
6000 CCH	4/85	4/1/85	404000	344175	79825		
10000 JOHNSON & JOHNSON	8/29/81	2/1/85	461285	262275			199010
1600 FLORIDA POWER LT	9/1/80	2/1/85	3155.9	293877	22132		
12000 TENNESSEE UTILITIES	6/1/80	2/1/85	271691	274320	(2629)		
500,000 TRUNICO INC STD	8/25/80	2/1/85	555000	500000	55000		
500,000 FIDELITY NATL MIG ASSN	5/1/80	2/1/85	500000	480156			19844
12200 ALLIANT PWR	1/12/80	4/1/85	291594	267813	22779		
500,000 HIRACULT INC NT	9/1/80	4/1/85	500000	478750			21250
7500 ALLIANT PWR	1/1/80	4/1/85	151592	161512	2080		
12000 CONAVER FIDELITY ASSN	9/80	4/1/85	349548	307820	41728		
15000 SUPRAVALVE SEARS	1/1/80	2/1/85	422886	372600	49786		
12000 SYNTRE	4/1/85	4/1/85	101196	76400	29796		
10000 SYNTRE	4/1/85	4/1/85	540982	345400			192582
400,000 EASTMAN KODAK CUSAD	1/1/80	4/1/85	389500	400000	(10500)		
300,000 FIDELITY BANKS 80	4/1/80	2/1/85	456250	499219			(42969)
2000 RYDER SYSTEMS	10/1/80	4/1/85	109648	92211	17437		
26664 MCI	4/1/85	4/1/85	423291	301800			121791
10000 RYDER HOMES	4/1/85	4/1/85	364188	401000	(36612)		
10000 GENERAL RE	4/1/85	4/1/85	558981	436440			122541
10000 APPLE COMPUTER	4/1/85	4/1/85	340000	420000	(80000)		
5200 RYDER SYSTEMS	10/1/80	4/1/85	428199	360062	68137		
5000 DIBOLD	11/1/81	4/1/85	440710	233518			207192
1,141 SIR UNIVERSAL FO	11/80	11/85	3	3	-		
200000 GRAPHIC SCAN CV	1/1/81	2/1/85	159000	200000			(41000)

TOTALS

T. Page 2 of 2

ENTER TOTALS ON SCHEDULE D

IDENTIFICATION NO 36 6125258

STATEMENT NO 6 (2 of 2) SCHEDULE OF CAPITAL GAINS & LOSSES YEAR ENDED 1973

[illegible]**ENTER TOTALS ON SCHEDULE D**

Total Net Gain

15196826

NAME THE KROC FOUNDATIONIDENTIFICATION NO. 26-6125238STATEMENT NO. 7YEAR ENDED 12/31/83

STATEMENT RE: OFFICIAL COMPENSATION, ETC.	TITLE & AVE HAS	CONTRIB TO LEISURE PLAN	EXPENSE ACCOUNT	COMPENSATION
RAY A KROC 2939 Villa La Jolla Dr. Suite 201 La Jolla CA 92037	Chairman of the Board - Director - Nominal	None	None	None
ROBERT L KROC #072 22 3438 4757 Sierra Madre Rd Santa Barbara CA 93110	PRESIDENT & Director - Full	20910	11810	304090
JOHN A KROC 2939 Villa La Jolla Dr. Suite 201 La Jolla CA 92037	Vice-President & Director - Part	None	None	None
FRED L TURNER 70 McDonalds Corporation McDonald's Plaza, Oakbrook IL 60451	Vice-President & Director - Nominal	None	None	None
LORRAINE E GRAY 17715 GULF BLVD #842 Reddington Shores FL 33708	Treasurer & Director - Nominal	None	None	None
BALLARD F SMITH PO Box 2000 San Diego CA 92120	Secretary & Director - Nominal	None	None	None
CH HOFFMAN 2939 Villa La Jolla Dr. Suite 201 La Jolla CA 92037	Assistant Secretary - Part	None	None	None
JOHN LEWIN # 207 14 4749 c/o 5290 Overpass Rd #225 Santa Barbara CA 93111	Assistant Secretary - Full	830	None	16535
		21740	11810	320625